Brain-derived neurotrophic factor (BDNF) helps restore neuronal function following mild traumatic brain injury. BDNF levels can be obtained in blood serum and more recently in saliva. However, the relationship between serum and salivary BDNF is poorly understood-especially in relation to alterations in BDNF levels following mild traumatic brain injury. In this study, serum and salivary BDNF were collected from a sample of 42 collegiate student athletes. Half of the participants were recently cleared by a physician and/or an athletic trainer to return-to-play after experiencing a sports-related concussion. The other half had not experienced a concussion within the past year and were matched by age, sex, sport, and time of sample. Results suggest that incidences of depression, anxiety, and stress were all elevated in the concussion group, relative to the control participants. When controlling for stress-related negative affect, serum BDNF was elevated in the concussion group. However, there was no difference in salivary BDNF. Serum and salivary BDNF were uncorrelated across the entire sample. Yet, these measures of BDNF were correlated in the concussion group, but not the control group. In sum, serum BDNF is elevated in concussion post return-to-play; however, further research is needed to explore the utility of salivary BDNF following concussion.
Introduction
In the United States, roughly 1.6 to 3.8 million sportsrelated concussions occur each year. 1, 2 Concussion is a mild traumatic brain injury (mTBI) defined as a complex pathophysiological process affecting the brain, induced by traumatic biomechanical forces. 3, 4 Brainderived neurotrophic factor (BDNF) is a protein in the neurotrophin family of growth factors that plays an important role in neuronal survival, synaptic plasticity, and neurogenesis. 5 In animal models of traumatic brain injury (TBI), BDNF helps restore synaptic connectivity and provides a neuroprotective role by reducing secondary brain injury. 6, 7 In human participants, acute BDNF levels are lower in TBI patients relative to controls, 8, 9 but higher in mTBI relative to moderate or severe TBI. 9 However, beyond these immediate effects of BDNF, there is limited information on the relationship between BDNF and TBI-particularly in mTBI or concussion, which is the most common form of TBI. 1, 2 There is a great deal of recent interest in establishing reliable biological correlates of concussion-especially sports-related concussion/mTBI. 10 Yet, the potential relationship between BDNF and concussion in this population is unclear.
BDNF is also associated with stress-related factors such as depression and anxiety, 11 which are additionally elevated following sports-related concussions. 12, 13 In particular, post-concussive symptoms of depression and anxiety are common and can take one to three months or more to normalize depending on the individual. 14 In some cases, it has been hypothesized that postconcussive symptoms may be undiagnosed anxiety or mood disorders caused by concussions. Thus, there is a need for research to determine the relationship between concussion and variation in BDNF levels, which may account for the effects of stress-related negative affect.
In humans, neural BDNF levels are typically indirectly measured in blood serum. 9, 15 Although serumbased measures are effective in detecting BDNF, they are invasive and require a trained phlebotomist. This procedure is commonly stressful and inconvenient. However, within the past decade, the detection of BDNF in human saliva 16, 17 has provided an easy to obtain, noninvasive, and relatively stress-free method of collecting BDNF. 15, 18 Indeed, differences in salivary BDNF have been linked to morning vs. evening personality type 19 and exercise-related training. 20 Yet, to the best of our knowledge, the relationship between salivary BDNF and concussion has not been assessed. Furthermore, the extent to which salivary-based measures of BDNF are a reliable substitute for serum-based measures is questionable, as several studies have shown that the two measures are unrelated. 19, 21 As mentioned above, there is much interest in establishing biomarkers of concussion, 10 if salivary BDNF is reliable, it would be an ideal biomarker given its ease of collection and accessibility. Accordingly, the current study aimed to assess the extent to which serum and salivary-based measures of BDNF (1) are altered in the later stages of concussion after athletes have been cleared to return-to-play and (2) are correlated with each other.
Methods

Participants
Forty-two collegiate athletes between the ages of 18 and 23 (Females ¼ 16, M ¼ 19.67, SD ¼ 1.24) from Northern Michigan University's athletic programs participated in the study. Half (n ¼ 21, M age ¼ 19.67) were recently cleared by an athletic trainer and/or physician to return-to-play after sustaining a concussion. Three of the concussed athletes did lose consciousness and two experienced back to back concussions prior to participating in the study. The other half (n ¼ 21, M age ¼ 19.67) of participants were controls without a history of concussion in the 12 months preceding the study. Controls were matched based on age, sex, sport, and time of sample collection (see Table 1 ). All participation was completely voluntary and written consent was obtained by every participant; all were compensated for their time.
DASS questionnaire
The Depression Anxiety Stress Scales (DASS) was given prior to sample collection. The DASS is composed of three self-report scales aimed to measure states of depression, anxiety, and stress. 22 Each scale is comprised of 14 statements, for a total of 42 items, participants are to answer each statement using a fourpoint severity scale to the degree in which they have experienced each statement over the past week. The maximum score for each scale is 42, a composite score for DASS ranges from 0 to 126.
Collection of BDNF samples
Fasting. All participants did not consume food or drink besides water at least one hour prior to data collection. 21 Usage of alcohol, nicotine, prescription, and over-the-counter medication was collected (see Table 1 ). Participants were scheduled based on their availability, ranging from 8:00 AM and 8:00 PM. Although time of sample varied across participants, time of sample was balanced across groups (see Table 1 ).
Serum. Blood samples were collected in 5 ml vacutainer serum separator tubes (Becton Dickinson, Franklin Lakes, NJ). Following collection, the serum separator tubes were immediately inverted four times and allowed to clot for 30 min at room temperature. Serum was separated via centrifugation at 3500 r/min for 10 min and 1 ml aliquots were transferred to sterile 2 ml cryovials (Nalgene, Rochester, NY). Samples were stored at À80 C until use.
Saliva. Saliva was collected by the passive drool method, because it is known to detect higher levels of BDNF when compared to the salivette method. 21 After pooling saliva in their mouth, participants used the saliva collection aid to force the saliva into a vial. At least 2.0 ml of saliva was collected from each participant. Samples were placed on ice immediately until further handling. All samples were centrifuged for 15 min at 4000 r/min to 4 C. Consistent with serum samples, saliva samples were stored at -80 C until analysis.
BDNF ELISA assays
Both saliva and serum BDNF levels were analyzed using an enzyme-linked immunosorbent assay (ELISA) kit (CYT306, Millipore Sigma). Assay of saliva samples were not diluted, while serum samples were diluted to a 1:32 ratio. Each assay was performed in duplicate. ELISA plate readings were performed using a microplate reader (Epoch2; BioTek Instruments, Inc., Winooski, VT, USA). Analysis was performed using Gen5 software (BioTek Instruments, Inc., Winooski, VT, USA). Standard curves were obtained for saliva (R 2 ¼ .992) and serum (R 2 ¼ .995).
Statistical analyses
Of the 42 participants, 39 yielded data for the serum analysis, 36 for the saliva analysis, and 35 participants had both serum and saliva data. To assess the relationship between groups (concussion vs. control) and DASS measures, independent samples t-tests were run on each DASS scale and the composite score. Separate analyses of covariance (ANCOVA) were used to test the effect of concussion group on serum and salivary BDNF while controlling for negative affect (i.e. DASS). Single-tailed Pearson correlations were used to test for a (positive) relationship between serum and salivary BDNF measures across the entire sample as well as separately for each group. Pearson correlations were also used to test for a relationship between BDNF levels and days since concussion and days since returnto-play.
Results
Days since return-to-play varied from 1 to 41 days (M ¼ 9.71, SD ¼ AE12.08). Days since concussion varied from 1 to 50 days (M ¼ 26.82, SD ¼ AE13.10). There was no significant relationship between days since concussion and days since return-to-play in the concussion participants, r ¼ .30, p ¼ .20.
DASS questionnaire
The concussion group exhibited significantly higher levels of depression, anxiety, stress, and total DASS measures compared to the control group (see Table 1 ). Thus, the concussion group displayed a non-specific increase in stress-related negative affect, relative to the control group.
Serum
There was an effect of group on serum BDNF levels, F(1, 36) ¼ 4.13, p < .05, g p 2 ¼ .10, where concussion participants (M ¼ 2.00, SE ¼ .099) had greater levels of BDNF than controls (M ¼ 1.70, SE ¼ .097). The total DASS score was not related to serum BDNF levels, F(1, 36) ¼ 1.00, p ¼ .32, g p 2 ¼ .03 (Figure 1(a) ). For concussion participants, the relationships between serum-based BDNF and days since return-to-play Table 1 . Comparison of participant groups.
Concussion
Control Comparison
Depression Anxiety Stress Scales. OTC: over the counter medication.
(r ¼ .18, p ¼ .46) as well as days since concussion (r ¼ .25, p ¼ .30) were not statistically significant.
Saliva
Observations of box and whisker plots indicated three outliers (2 concussion and 1 control) that were > three SDs above the respective group M. These outliers were excluded from all analyses involving saliva. There was no effect of group on salivary BDNF levels, F(1, 30) ¼ .36, p ¼ .55, g p 2 ¼ .01. BDNF levels in concussion participants (M ¼ .11, SE ¼ .02) did not differ from control participants (M ¼ .09, SE ¼ .02, see Figure 1(b) ). The total DASS score was not related to salivary BDNF levels, F(1, 30) ¼ .16, p ¼ .70, g p 2 ¼ .00. In the concussion group, a strong positive correlation was found between salivary BDNF and days since return-to-play, r ¼ .69, p ¼ .004. However, no such correlation was found between salivary BDNF and days since concussion, r ¼ .05, p ¼ .87.
Relationship between salivary and serum-based measures of BDNF
Across all participants, the relationship between serum and salivary BDNF was weak and did not reach statistical significance, r ¼ .05, p ¼ .40 (Figure 1(c) ).
However, a significant relationship was found between salivary and serum BDNF in the concussion (r ¼ .49, p ¼ .03) group, but not the control (r ¼ -.25, p ¼ .16) group. When controlling for time of sample collection and days since concussion, the relationship remained significant, r ¼ .61, p ¼ .01.
Discussion
Elevated serum BDNF was found in collegiate athletes after being cleared to return-to-play following concussion in comparison to controls (see Figure 1(a) ). Conversely, there was no difference between groups in salivary BDNF (see Figure 1(b) ). In addition, serum and salivary BDNF were not correlated with each other across groups. However, within the concussion group, salivary and serum BDNF were strongly correlated (see Figure 1(c) ). Thus, serum-based BDNF appears to be elevated in concussion post return-to-play, but salivary BDNF was not different between groups.
Our finding of elevated serum BDNF in concussion post return-to-play adds to the understanding of the brain's response to minimize secondary injury following neurotrauma. Recently, reductions in dayof-injury 9 serum BDNF have been observed in concussion. However, it has been hypothesized that although BDNF levels are initially lower, they later increase, as higher levels of day-of-injury BDNF are predictive of more successful recovery. 9 All of the concussion participants in the present study were beyond the acute phase and already cleared to return-to-play. Taken together with data from this previous study, our results suggest that the time-course for serum-based BDNF is dynamic with initial levels being relatively lower and later levels being relatively higher. This notion is consistent with animal models where BDNF plays a neuroprotective role in reducing secondary brain injury. 6, 7 That is, secondary brain injury can arise from various ischemic, inflammatory, cytotoxic, and apoptotic functions resulting from the initial injury, and evidence suggests increases in BDNF following secondary brain injury minimizes these effects. 10 In addition, BDNF is thought to repair synaptic connectivity of damaged brain areas during recovery. 6, 7 Given that our samples were collected after participants were cleared to return-to-play, it is likely that our BDNF levels represent secondary brain injury and/or recovery phases. In summary, our findings indicate that serum-based BDNF levels are higher post return-to-play following concussion-suggesting that the recovery process is ongoing even after acute effects have subsided and athletes are cleared to return-to-play. On the other hand, salivary BDNF measures were not significantly different between groups. This relationship was absent even though we were able to detect BDNF, which has previously been inconsistent. 18 We found that serum and salivary BDNF measures are unrelated across the entire sample. This finding is consistent with previous research comparing salivary and serum BDNF. 19, 21 However, a strong correlation was found in the concussion group between saliva and serum-based BDNF, indicating there is convergence across salivary and serum-based measures of BDNF in concussion. In short, our results add to previous research suggesting that saliva is not a universally reliable measure for BDNF 21 and does not appear to distinguish between concussion and control groups. Yet, according to our findings, saliva may reliably measure BDNF under certain circumstances-namely after a recent concussion. Thus, the utility of salivary measures shows some promise in the ability to detect BDNF that correlates with serum-based BDNF. Future research is needed to further assess the potential of salivary BDNF following concussion.
The present study had several limitations that should be considered when interpreting our results and when designing future research. First, there was variability in the time of our samples. However, this factor was matched across participant groups and therefore unlikely to have affected our group comparisons. Nevertheless, future research should aim to collect samples at a consistent time of day. Second, diurnal variation was not accounted for in our study and has previously been related to BDNF levels in plasma samples of men, but not women (or serum samples of either sex). 23 Therefore, time of sample collection may more appropriately be set relative to the participant's average wake time rather than an absolute time of day. Third, there was also variability in the time course of concussion recovery. Future research should aim to collect samples during a smaller window within the time course of recovery. In addition, the collection of multiple samples in each individual across the time course of recovery would strengthen our understanding of the dynamics in BDNF levels during recovery. Fourth, we had a relatively small sample size. Future research should replicate our effects in a larger sample. In sum, we used a highly matched sample, controlled for food and liquid consumption prior to sample collection, followed the standardized passive drool collection method, and controlled for stress-related negative affect. Yet, further standardization of BDNF collection should be implemented in future research. In particular, the time of sample acquisition relative to injury and chronobiology should be standardized.
Conclusion
Depression, anxiety, and stress levels were elevated in athletes with concussion. Based on our findings, no relationship exists between salivary and serum BDNF measures in the control group, yet this relationship was significant in the concussion group. Serum-based measures of BDNF may be useful in measuring the effects of concussion post return-to-play, but salivary measures are likely not effective at detecting group differences at this timeframe.
